Platelet count alone can't define ITP treatment success—and what multi-pathway immune targeting actually requires.
Dr. Srikanth Nagalla
Advertisement
Articles by Dr. Srikanth Nagalla
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
The Battle to Own the GLP-1 Patient Journey
3
Pharmaceutical Executive Daily: FDA Approves Fayuvi
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5